Changing how we talk about clinical trials

Multiple sclerosis (MS) patient Elizabeth Kinder tells us why she participated in a clinical trial and why the language needs to change.

Biogen gears up for Alzheimer's drug launch

There are serious doubts about whether the FDA will approve Biogen’s Alzheimer’s candidate aducanumab – but is gearing up to file it with the regulator and is already looking ahead to a pot

Novartis' Mayzent EU approval offers SPMS patients new optio...

Novartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease.

NHS patients to get easier access to MS pill after NICE reth...

Patients in England are to get easier access to Merck KGaA’s multiple sclerosis drug Mavenclad after NICE dropped requirements for a special MRI scan before prescription.

Brisk trade in risky three-drug 'bet' option after BMS/Celge...

Bristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and the focus has shifted on to whether Celgene shareholders will

Mavenclad helps Merck shrug off Rebif decline in MS